Gapping down
In reaction to disappointing earnings/guidance: TEX -7.8%
Select oil/gas related names showing early weakness: E -1.2%, SDRL -1%, TOT -1%, BP -0.7%
Other news: NPSP -14.0% (FDA Advisory Committee votes 8-5 the recommend approval of Natpara), NETE -7% (pulling back following Friday's advance), ACHN -3% (still checking), INSY -2.9% (disclosed it received a subpoena requesting documents regarding Subsys), ALXN -1.8% (reports 5 yr results of Asfotase Alfa in ped patients with severe HPP), WB -1.5% (still checking), BHP -0.8% (weak industrial production figures out of China), DE -0.6% (in sympathy with TEX), CAT -0.5% (in sympathy with TEX)
Analyst comments: RAX -3.9% (downgraded to Neutral from Overweight at JP Morgan), TSLA -2.2% (weakness attributed to Morgan Stanley analyst comments, suggesting stock may be a bit ahead of itself), PKD -1.6% (downgraded to Equal Weight from Overweight at a boutique firm), PLOW -1.2% (downgraded to Neutral from Outperform at Robert W. Baird), UBS -1.2% (downgraded to Equal Weight from Overweight at Barclays), TRP -1% (downgraded to Sell from Neutral at Goldman), CLW -0.7% (downgraded to Neutral at DA Davidson)
In reaction to disappointing earnings/guidance: TEX -7.8%
Select oil/gas related names showing early weakness: E -1.2%, SDRL -1%, TOT -1%, BP -0.7%
Other news: NPSP -14.0% (FDA Advisory Committee votes 8-5 the recommend approval of Natpara), NETE -7% (pulling back following Friday's advance), ACHN -3% (still checking), INSY -2.9% (disclosed it received a subpoena requesting documents regarding Subsys), ALXN -1.8% (reports 5 yr results of Asfotase Alfa in ped patients with severe HPP), WB -1.5% (still checking), BHP -0.8% (weak industrial production figures out of China), DE -0.6% (in sympathy with TEX), CAT -0.5% (in sympathy with TEX)
Analyst comments: RAX -3.9% (downgraded to Neutral from Overweight at JP Morgan), TSLA -2.2% (weakness attributed to Morgan Stanley analyst comments, suggesting stock may be a bit ahead of itself), PKD -1.6% (downgraded to Equal Weight from Overweight at a boutique firm), PLOW -1.2% (downgraded to Neutral from Outperform at Robert W. Baird), UBS -1.2% (downgraded to Equal Weight from Overweight at Barclays), TRP -1% (downgraded to Sell from Neutral at Goldman), CLW -0.7% (downgraded to Neutral at DA Davidson)